About the Company
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALKS News
Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 45% Undervaluation?
How far off is Alkermes plc ( NASDAQ:ALKS ) from its intrinsic value? Using the most recent financial data, we'll ...
Alkermes PLC
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Client Profile: Alkermes Plc
A special interest's lobbying activity may go up or down over time, depending on how much attention the federal government is giving their issues. Particularly active clients often retain multiple ...
First Week of March 17th Options Trading For Alkermes (ALKS)
Investors in Alkermes plc (Symbol: ALKS) saw new options become available this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALKS ...
ALKS.OQ - Alkermes Plc | Stock Price & Latest News | Reuters
Alkermes Public Limited Company is a fully integrated biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed ...
Alkermes to Present at the 41st Annual J.P. Morgan Healthcare Conference
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary ...
Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
DUBLIN, Jan. 17, 2023 /PRNewswire/ -- Alkermes plc ALKS today announced that nemvaleukin alfa (nemvaleukin), the company's investigational, novel engineered interleukin-2 (IL-2) variant ...
AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?
AstraZeneca AZN will report fourth-quarter and full-year 2022 results on Feb 9. In the last reported quarter, the company ...
Amarin Mails Letter To Shareholders Highlighting Sarissa's Myths Vs. The Facts
Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the“Company”) today announced that it has mailed a letter to shareholders addressing the false and misleading statements made by Sarissa Capital ...
Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 45% Undervaluation?
How far off is Alkermes plc (NASDAQ:ALKS) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash ...
Alkermes (ALKS) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site ...
Loading the latest forecasts...